FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVIB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

OMB ADDDOMAI

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Peterson Kristine (Last) (First) (Middle) C/O IMMUNOGEN, INC.					Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN] Date of Earliest Transaction (Month/Day/Year) 06/16/2021						(Ch	eck all applic	cable) or (give title	Person(s) to I: 10% (Other below	Owner (specify
830 WINTER STREET (Street) WALTHAM MA 02451			02451	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							ndividual or Joint/Group Filing (Check Applicable b) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(S		(Zip)												
(e.g., pu 1. Title of						2A. Deemed Execution Date, if any (Month/Day/Year) IVE Securities Acquints, calls, warrants, or of Derivative Securities Acquired (Nature 1988)			4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		Price Price Price Amount les	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) Illy Owned S. Price of Derivative Security (Instr. 5) Int. 8. Price of Derivative Security (Instr. 5)		Ownersh Form: Direct (Di or Indirect	Beneficial Ownership (Instr. 4)
	Security	ecurity	my			(A) or Disposed of (D) (Instr. 3, 4 and 5)		nstr.					Following Reported Transaction(s (Instr. 4)	n(s) (I) (Instr.	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Deferred Share Unit	\$0 ⁽¹⁾	06/16/2021		A		15,000		(3)(2)	(2)	Common Stock ⁽²⁾	15,000	\$0 ⁽¹⁾	59,954	D	
Stock Option (right to buy)	\$6.77	06/16/2021		A		44,000		(4)	06/16/2031	Common Stock	44,000	\$6.77	44,000	D	

Explanation of Responses:

- 1. The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- 2. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- $3. \ The deferred share units vest quarterly on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date.$
- 4. Exercisable as to 11,000 shares on each of 9/1/21, 12/1/21, 3/1/22 and 6/1/22, contingent upon the individual remaining a director as of each vesting date.

/s/ Joseph J. Kenny, attorney in 06/17/2021 fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.